Lite Strategy, Inc.(LITS)

Biotechnology · San Diego, CA

$1.43+0.03 (+1.79%)

Delayed quote: Oct 6, 2026, 12:09 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T16:12:53.468Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:12:53.468Z.

Quote observation: 2026-10-06T16:09:19.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -12,800,000
Quote market capitalization: 48,485,910
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 5,706,000

FMP input reference: 0dc40ddd6b0c815ea8fb06d6c0f10798674f4babd9a38c246e46e89e51900236

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

LITS EBITDA Yield Metrics

EBITDA YIELD

N/A

LITS Competitors' EBITDA Yield

LITS

Lite Strategy, Inc.

Current

Market Cap

$48.49M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

POCI

Precision Optics Corporation, Inc.

vs LITS

Market Cap

$48.27M

EBITDA Yield

N/A

TTM Avg

0.84%

3Y Avg

0.84%

5Y Avg

0.84%

APLM

Apollomics, Inc.

vs LITS

Market Cap

$49.85M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CELU

Celularity Inc.

vs LITS

Market Cap

$50.37M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MBOT

Microbot Medical Inc.

vs LITS

Market Cap

$49.90M

EBITDA Yield

N/A

TTM Avg

0.89%

3Y Avg

5.54%

5Y Avg

4.70%

ELOX

Eloxx Pharmaceuticals, Inc.

vs LITS

Market Cap

$51.13M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INMB

INmune Bio, Inc.

vs LITS

Market Cap

$50.78M

EBITDA Yield

N/A

TTM Avg

3.11%

3Y Avg

2.71%

5Y Avg

2.71%

COCH

Envoy Medical, Inc.

vs LITS

Market Cap

$51.34M

EBITDA Yield

N/A

TTM Avg

0.59%

3Y Avg

0.59%

5Y Avg

0.59%

RANI

Rani Therapeutics Holdings, Inc.

vs LITS

Market Cap

$51.28M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EXOZ

eXoZymes, Inc.

vs LITS

Market Cap

$51.42M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Lite Strategy, Inc. (LITS)	$48.49M	N/A	N/A	N/A	N/A
Precision Optics Corporation, Inc. (POCI)vs ›	$48.27M	N/A	0.84%	0.84%	0.84%
Apollomics, Inc. (APLM)vs ›	$49.85M	N/A	N/A	N/A	N/A
Celularity Inc. (CELU)vs ›	$50.37M	N/A	N/A	N/A	N/A
Microbot Medical Inc. (MBOT)vs ›	$49.90M	N/A	0.89%	5.54%	4.70%
Eloxx Pharmaceuticals, Inc. (ELOX)vs ›	$51.13M	N/A	N/A	N/A	N/A
INmune Bio, Inc. (INMB)vs ›	$50.78M	N/A	3.11%	2.71%	2.71%
Envoy Medical, Inc. (COCH)vs ›	$51.34M	N/A	0.59%	0.59%	0.59%
Rani Therapeutics Holdings, Inc. (RANI)vs ›	$51.28M	N/A	N/A	N/A	N/A
eXoZymes, Inc. (EXOZ)vs ›	$51.42M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

LITS EBITDA Yield Metrics

LITS Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics